Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol

Filing content

Vistagen announced preliminary positive data from the open-label extension of its Phase 3 PALISADE-4 study of fasedienol for social anxiety disorder, showing good tolerability and symptom improvement. The company plans to meet with the FDA this quarter to discuss the regulatory path.